June 15, 2021 : Issue #1141

TOP STORIES — Diabetes News and Research

The Effects of GLP-1 Receptor Agonists on Cardiovascular Events

HbA1c Changes as a Predictor of Cardiovascular Disease Incidence

Adding Pramlintide to Artificial Pancreas Systems

MOST POPULAR ARTICLES OF THE MONTH

#1 New Weight Loss Combo

#2 Key Exercises and Training for Aging Successfully and Living Your Best Life

#3 FDA Approves 1st AI Insulin Pen Cap, Making Insulin Dosing Simple

Before Amylin hit it big with Byetta and Bydureon, and their employees and stock holders were well rewarded with their eventual purchase by BMS and AZ, they had another product that many of us thought would be a big hit. You may remember a product called SYMLIN® (pramlintide acetate) that is an analog of the pancreatic hormone amylin that the company took their name from.

This drug looked to be a great product for both type 1 and type 2 patients, and had some of the same great qualities found in the GLP-1 analog class, but it needed multiple daily injections and it never really caught on with the type 1 crowd. As the success of the GLP-’s grew the use of pramlintide almost disappeared.

This week our intern, George McConnell, PharmD. Candidate, LECOM School of Pharmacy, takes a look at a possible new way to deliver pramlintide, and how valuable it can be for type 1 patients, especially if they are on a closed loop system.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

With magnet strength in wireless charging technology going up, it poses a problem for heart devices. AHA June 2, 2021

How important is GLP-1 RA effect on Hemoglobin A1c reduction in determining cardiovascular risk? 

HbA1c variability and swings between hypo- and hyperglycemia can increase risk of developing cardiovascular disease.

The pancreas secretes both insulin and amylin, so should an artificial pancreas system provide insulin and pramlintide?